This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Cellectis SA

Description: UCART22 is a chimeric antigen receptor (CAR-T) treatment candidate presumably targeting the CD22 antigen.

Deal Structure: Cellectis and MD Anderson
In September 2015, Cellectis and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors. The alliance will build on MD Andersons translational and preclinical and clinical teams in leukemia and myeloma, coupled with Cellectis allogeneic CAR T-cell therapy approach and manufacturing capabilities, to pursue the development of Cellectis candidate products UCARTCS1, UCART22, UCART38 in T-cell ALL and UCART123 in a rare non curable disease BPDCN.

Partners: University of Texas MD Anderson Cancer Center

UCART22 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug